Original ArticleCorrelation of Quantitative Measurements with Diabetic Disease Severity Using Multiple En Face OCT Angiography Image Averaging
Section snippets
Methods
This retrospective, cross-sectional cohort study received institutional review board approval from Salus IRB (Austin, TX). This study complied with the Health Insurance Portability and Accountability Act of 1996 and followed the tenets of the Declaration of Helsinki. All individuals signed a written informed consent before participating in the study.
Demographics
Eighty-four eyes of 55 patients, including normal control participants and those with varying levels of DR, met the inclusion criteria. Twenty-eight eyes (19 patients) were from healthy, age-matched controls, 11 eyes (8 patients) were from diabetics without DR, 9 eyes (7 patients) had mild DR, 10 eyes (7 patients) had moderate DR, 5 eyes (3 patients) had severe DR, and 21 eyes (15 patients) had proliferative DR. The average hemoglobin A1C of the DR cohort was 7.0±1.8%. Baseline characteristics
Discussion
We previously demonstrated that image averaging in RVO eyes showed improved visualization of angiographic en face images. In this study, we evaluated the correlation between quantitative microvascular changes on spectral-domain OCTA with BCVA and severity of DR. Univariate analysis demonstrated that the correlation with BCVA was statistically significant for all quantitative variables except for FAZ size in the single images and for the SRL inferior PD, SRL nasal PD, SRL temporal PD, and DRL
References (48)
- et al.
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales
Ophthalmology
(2003) - et al.
Efficacy of ranibizumab in eyes with diabetic macular edema and macular nonperfusion in RIDE and RISE
Ophthalmology
(2018) - et al.
Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity
Ophthalmology
(2017) - et al.
Fluorescein angiography complication survey
Ophthalmology
(1986) - et al.
Optical coherence tomography angiography
Prog Retin Eye Res
(2018) - et al.
Impact of multiple en face image averaging on quantitative assessment from optical coherence tomography angiography images
Ophthalmology
(2017) - et al.
Microaneurysm imaging using multiple en face OCT angiography image averaging: morphology and visualization
Ophthalmol Retina
(2020) - et al.
Phase-variance optical coherence tomography: a technique for noninvasive angiography
Ophthalmology
(2014) - et al.
Importance of focus in OCT angiography
Ophthalmol Retina
(2018) - et al.
OCT angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: a prospective study
Ophthalmology
(2019)
Visual acuity is correlated with the area of the foveal avascular zone in diabetic retinopathy and retinal vein occlusion
Ophthalmology
The electroretinogram in diabetic retinopathy
Surv Ophthalmol
Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor
Ophthalmology
Diabetic retinopathy—ocular complications of diabetes mellitus
World J Diabetes
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Eye Vis (Lond)
Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13
Ophthalmology
Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography
JAMA Ophthalmol
Adverse reactions to fluorescein angiography
Acta Ophthalmol (Copenh)
Repeatability and reproducibility of superficial macular retinal vessel density measurements using optical coherence tomography angiography en face images
JAMA Ophthalmol
Association between vessel density and visual acuity in patients with diabetic retinopathy and poorly controlled type 1 diabetes
JAMA Ophthalmol
Optical coherence tomographic angiography in type 2 diabetes and diabetic retinopathy
JAMA Ophthalmol
Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy
JAMA Ophthalmol
Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography
Invest Ophthalmol Vis Sci
Quantification of retinal capillary nonperfusion in diabetics using wide-field optical coherence tomography angiography
Retina
Cited by (9)
Effect of caffeine on superficial retinal vasculature of the macula in high myopes using optical coherence tomography angiography – A pilot study
2022, Journal of OptometryCitation Excerpt :Averaging multiple OCTA acquisitions could enhance image quality5051 and be more sensitive in detecting differences,52 especially when the scan size is large (such as 6 × 6 mm) with low resolution in pixel/mm.53 Previous studies have documented the advantage of image averaging in examining retinal vein occlusion54 and diabetic retinopathy.55 Only one high quality OCTA image was captured in the current study, which could be due to the instrument being incapable of detecting small changes.
Correlation of Diabetic Disease Severity to Degree of Quadrant Asymmetry in En Face OCTA Metrics
2022, Investigative Ophthalmology and Visual ScienceChoriocapillaris Flow Deficit in Tubercular Serpiginous-Like Choroiditis with and without Paradoxical Worsening
2022, Ocular Immunology and Inflammation
Financial Disclosure(s): The author(s) have made the following disclosure(s): J.J.J.: Consultant – Carl Zeiss Meditec, Inc, Alimera Sciences, Allergan, Google.
D.J.G.Y.: Financial support – Johnson and Johnson Vision Care.
M.H.C.: Employee – Topcon Medical Systems, Inc.
S.R.S.: Consultant – Optos, Heidelberg, Centervue, Allergan, Amgen, Roche/Genentech, Novartis, Regeneron, 4DMT, Carl Zeiss Meditec, Inc; Financial support – Carl Zeiss Meditec, Inc.
Q.V.H.: Financial support – Johnson and Johnson Vision Care
HUMAN SUBJECTS: Human subjects were included in this study. The human ethics committees at Salus IRB approved the study. All research complied with the Health Insurance Portability and Accountability (HIPAA) Act of 1996 and adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Jung, Shi, Nassisi, Marion, Sadda, Hoang
Analysis and interpretation: Jung, Yu, Zeng, Chen, Shi, Nassisi, Marion, Sadda, Hoang
Data collection: Jung, Yu, Zeng, Chen, Hoang
Obtained funding: Supported in part by Research to Prevent Blindness, New York, New York (unrestricted grant and Career Development Award [Q.V.H.]); and the National Eye Institute/National Institutes of Health, Bethesda, Maryland (grant no.: 1 K08 EY023595 [Q.V.H.]). The sponsor or funding organization had no role in the design or conduct of this research.
Overall responsibility: Jung, Yu, Zeng, Chen, Shi, Nassisi, Marion, Sadda, Hoang